Start GLP-1 Weight Loss in 2026: Compare Wegovy, Zepbound, Foundayo & Oral Options
GLP-1 treatment has moved beyond the original Ozempic vs. Wegovy conversation. In 2026, people considering medical treatment for obesity may encounter weekly semaglutide, higher-dose Wegovy HD, oral Wegovy, weekly tirzepatide, and the new oral GLP-1 medicine Foundayo (orforglipron) by Eli Lilly.
The important question is no longer simply "Which GLP-1 is strongest?" A better approach is to compare the medicines by indication, clinical evidence, route, tolerability, cardiovascular or sleep-apnea considerations, cost, access, long-term maintenance, and the person's broader health goals.
Updated: September 27, 2026 | Regulatory reference: U.S. FDA labeling | Scope: Adult obesity treatment unless otherwise stated
What Changed in GLP-1 Weight Loss Treatment in 2026?
The obesity-medicine landscape changed materially between 2025 and 2026. Several developments make older comparison articles incomplete.
1. Wegovy is no longer injection-only
In the United States, Wegovy now includes both subcutaneous injections and oral tablets. The injection formulation includes the standard maintenance doses and the higher-dose 7.2 mg Wegovy HD option. Oral Wegovy uses a once-daily 25 mg maintenance dose for adult weight management under the current U.S. labeling.
.png)
The oral formulation is important because route of administration can strongly affect treatment acceptance. Some people dislike injections; others may prefer a weekly injection to a daily pill. That is a practical adherence issue rather than a simple question of efficacy.
2. Foundayo introduces another oral pathway
Foundayo (orforglipron) was approved by the FDA on April 1, 2026. It is an oral, nonpeptide, small-molecule GLP-1 receptor agonist taken once daily. Its U.S. prescribing information allows administration with or without food and uses a gradual dose-escalation schedule.
The current FDA-approved maximum dose is 17.2 mg once daily. This is important because the pivotal ATTAIN-1 study also evaluated an earlier 36 mg investigational formulation; the trial dose should not be confused with the currently marketed U.S. dosing schedule.
3. Tirzepatide remains a fundamentally different molecule
Zepbound contains tirzepatide, which activates both the GLP-1 and GIP receptors. It is therefore more accurate to describe Zepbound as a dual incretin GLP-1/GIP agonist, rather than simply calling it another GLP-1 drug.
In the 2025 SURMOUNT-5 randomized head-to-head trial, adults with obesity but without type 2 diabetes receiving maximum tolerated doses had greater average weight reduction with tirzepatide than with semaglutide. That result is clinically important, but it does not mean the same drug is automatically appropriate for every patient.
4. The clinical question has shifted from "How much weight can I lose?" to "What outcome matters?"
Weight loss remains central, but obesity treatment increasingly involves several targets: body weight, waist circumference, blood glucose, cardiovascular risk, obstructive sleep apnea, physical function, nutritional adequacy, muscle preservation, treatment burden and long-term maintenance.
This is one reason a responsible 2026 comparison should avoid declaring a universal "best GLP-1." Different medicines have different evidence bases and different labeled uses.
2026 GLP-1 and Incretin Weight-Loss Comparison
The table below focuses on major U.S. prescription options relevant to adult weight management. It is a comparison framework, not a ranking.
↔ Swipe the table sideways to see all columns on mobile.
| Medicine / Brand | Active ingredient | Type | Route | Adult weight-management role | Important distinguishing feature |
|---|---|---|---|---|---|
| Wegovy | Semaglutide | GLP-1 receptor agonist | Once-weekly injection | Chronic weight management | Established obesity evidence; also has a U.S. FDA indication for reducing major cardiovascular events in adults with established CVD plus overweight or obesity. |
| Wegovy HD | Semaglutide 7.2 mg | GLP-1 receptor agonist | Once-weekly injection | Higher-dose adult weight management | FDA-approved in 2026 after the STEP UP program studied higher-dose semaglutide. |
| Wegovy pill | Semaglutide 25 mg | GLP-1 receptor agonist | Once-daily tablet | Adult weight management | Provides an oral semaglutide route without weekly injections. |
| Zepbound | Tirzepatide | GLP-1/GIP dual agonist | Once-weekly injection | Chronic weight management | Also FDA-approved in the U.S. to treat moderate-to-severe obstructive sleep apnea in adults with obesity. |
| Foundayo | Orforglipron | GLP-1 receptor agonist | Once-daily tablet | Adult weight management | New oral small-molecule GLP-1 option; no need to take the tablet fasting under its U.S. labeling. |
| Saxenda | Liraglutide | GLP-1 receptor agonist | Once-daily injection | Weight management | Earlier-generation GLP-1 therapy; still an approved treatment option, depending on market and patient circumstances. |
Wegovy vs. Zepbound: what is actually different?
| Factor | Wegovy / Semaglutide | Zepbound / Tirzepatide |
|---|---|---|
| Primary mechanism | GLP-1 receptor agonism | GLP-1 + GIP receptor agonism |
| Injection frequency | Weekly | Weekly |
| Oral option in U.S. 2026 | Yes — oral Wegovy | No oral Zepbound equivalent in the current U.S. obesity label |
| Higher-dose development | Wegovy HD 7.2 mg approved in 2026 | Approved weekly maintenance range includes 5–15 mg |
| Cardiovascular indication | Yes, for a defined population with established CVD plus overweight/obesity | Not the same FDA-labeled cardiovascular indication |
| Obstructive sleep apnea indication | Not the same U.S. indication | Yes, adults with obesity and moderate-to-severe OSA |
| Direct head-to-head obesity data | Yes — SURMOUNT-5 directly compared maximum tolerated doses of tirzepatide and semaglutide. | |
↔ Swipe the table sideways to see all columns on mobile.
The table illustrates why "best GLP-1" is an incomplete question. Someone prioritizing an oral route, someone with established cardiovascular disease, and someone with obesity-related sleep apnea may be evaluating different clinical considerations.
What Do the 2025–2026 Trials Actually Show?
Clinical trial percentages are useful for understanding the scale of expected treatment effects, but they are not interchangeable. Trial populations, treatment duration, dose, adherence, lifestyle intervention and statistical estimands differ.
SURMOUNT-5: Tirzepatide vs. Semaglutide
The most informative direct comparison is the phase 3b SURMOUNT-5 trial. It randomized 751 adults with obesity but without type 2 diabetes to maximum tolerated tirzepatide or maximum tolerated semaglutide and followed them for 72 weeks.
This was a Lilly-funded trial. The result is a direct randomized comparison, but it was conducted in a specific population and at maximum tolerated doses. It should not be converted into a universal prediction for an individual patient.
STEP UP: Higher-dose semaglutide 7.2 mg
STEP UP evaluated once-weekly semaglutide 7.2 mg versus semaglutide 2.4 mg and placebo in adults with obesity without diabetes. At week 72, the treatment-policy estimand showed approximately 18.7% mean weight loss with 7.2 mg and 15.6% with 2.4 mg.
Under the trial-product estimand, which estimates the effect among participants adhering to the assigned treatment without rescue intervention, the figures were approximately 20.7% and 17.5%, respectively.
The distinction between these estimands matters. The larger number should not be presented as the guaranteed real-world result for every patient.
OASIS 4: Oral semaglutide 25 mg
Oral semaglutide also moved from research into clinical practice. In the OASIS 4 randomized trial, once-daily oral semaglutide 25 mg produced an estimated mean 13.6% reduction in body weight at week 64, compared with 2.2% with placebo.
Gastrointestinal adverse events were more common with oral semaglutide than with placebo in the study. This reinforces a recurring GLP-1 principle: route convenience does not eliminate dose-related tolerability issues.
Foundayo: Orforglipron
The ATTAIN program established the evidence base for Foundayo. In the pivotal study underlying the U.S. approval, the current FDA label reports a week-72 mean body-weight change of approximately −11.1% with the approved-equivalent 17.2 mg once-daily dose in adults without diabetes, compared with approximately −2.1% with placebo in the randomized population.
The original NEJM ATTAIN-1 publication used the investigational 36 mg formulation and reported an 11.2% mean reduction in body weight in the 36 mg group. Those numbers should not be confused with the marketed 17.2 mg tablet strength.
Evidence snapshot
| Study | Treatment | Duration | Reported weight change | How to interpret it |
|---|---|---|---|---|
| SURMOUNT-5 | Tirzepatide vs semaglutide | 72 weeks | −20.2% vs −13.7% | Direct randomized head-to-head comparison. |
| STEP UP | Semaglutide 7.2 mg vs 2.4 mg vs placebo | 72 weeks | −18.7% vs −15.6% vs −3.9% under treatment-policy estimand | Important evidence for the higher-dose Wegovy HD strategy. |
| OASIS 4 | Oral semaglutide 25 mg vs placebo | 64 weeks | −13.6% vs −2.2% | Supports oral semaglutide as a weight-management option. |
| ATTAIN-1 / current FDA label | Foundayo 17.2 mg vs placebo | 72 weeks | −11.1% vs −2.1% in adults without diabetes | Reflects the current approved-equivalent dose in U.S. labeling. |
How Should You Approach GLP-1 Treatment Selection in 2026?
A more useful starting question is: "Which treatment characteristics match the person's clinical needs and practical constraints?"
1. Start with the treatment goal
Goals may include substantial weight reduction, improving obesity-related metabolic disease, reducing cardiovascular risk, improving sleep apnea, preserving physical function, or maintaining previously achieved weight loss.
These objectives do not necessarily point to the same treatment.
2. Look at route preference
| If the priority is... | Relevant options to discuss |
|---|---|
| Weekly treatment rather than daily treatment | Wegovy injection, Wegovy HD, Zepbound |
| Oral treatment | Oral Wegovy or Foundayo in the U.S. |
| A medicine with an established cardiovascular-risk reduction indication in a defined obesity/CVD population | Wegovy injection |
| Obesity with moderate-to-severe obstructive sleep apnea | Zepbound has a U.S. FDA indication for this population |
| Higher-dose semaglutide following response and tolerability assessment | Wegovy HD 7.2 mg |
3. Consider diabetes and other medications
GLP-1 and incretin medicines can affect glucose levels and gastrointestinal absorption. The relevance of other glucose-lowering therapies, insulin, sulfonylureas and orally administered medicines varies by patient.
Foundayo's current label specifically notes that it delays gastric emptying and may affect absorption of concomitant oral medicines. Similar gastric-emptying considerations appear in semaglutide and tirzepatide labeling.
4. Consider cardiovascular and sleep-apnea history
The difference between a weight-loss indication and an outcome-specific indication matters. Wegovy injection has a U.S. FDA indication for reducing major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity.
Zepbound has a U.S. FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity. The approval was based on randomized placebo-controlled trials showing reductions in apnea-hypopnea index and body weight.
5. Consider tolerability before chasing the highest dose
Higher doses are not automatically better for every individual. Dose escalation exists partly to improve tolerability. Nausea, vomiting, diarrhea, constipation, abdominal discomfort and other gastrointestinal symptoms are common across the class.
A treatment that is technically potent but poorly tolerated or difficult to continue may be less useful than a treatment that can be taken consistently under appropriate medical supervision.
How to Start GLP-1 Weight Loss Safely
Starting a GLP-1 medicine should be treated as a structured obesity-management program rather than simply obtaining a prescription.
Step 1: Confirm that medication treatment is appropriate
In U.S. labeling for the major obesity medicines, adult treatment generally involves obesity or overweight with an appropriate weight-related medical condition, together with reduced-calorie eating and increased physical activity. The exact criteria and product labeling differ between medicines.
Step 2: Review medical history and contraindications
Review previous pancreatitis, gallbladder disease, gastrointestinal disorders, diabetes treatment, diabetic retinopathy, kidney problems, allergies, pregnancy plans and personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Step 3: Establish baseline measurements
Useful baseline information may include:
- Body weight and BMI
- Waist circumference
- Blood pressure
- Glucose and HbA1c when clinically appropriate
- Lipid profile when indicated
- Kidney and liver function where appropriate
- Medication and supplement review
- Baseline physical function and strength, particularly in older adults or those at risk of sarcopenia
Step 4: Start low and escalate according to the prescribing information
Do not copy someone else's dose-escalation schedule from social media. Wegovy, Zepbound and Foundayo have different starting doses and titration schedules. The purpose of escalation is to reach a clinically useful dose while managing tolerability.
Step 5: Make food quality part of the treatment
Appetite suppression can unintentionally reduce total nutritional intake. That can become important when protein, fiber, fluids, micronutrients or overall calorie intake falls too low.
A practical GLP-1 nutrition strategy emphasizes adequate protein, minimally processed nutrient-dense foods, vegetables, fruit, legumes, whole grains where tolerated, hydration and individualized calorie intake.
Step 6: Add resistance training
Weight reduction is not identical to fat reduction. Some lean mass is lost during substantial weight loss. Current evidence supports resistance exercise, adequate protein intake and body-composition monitoring when appropriate to help protect muscle and physical function.
See also: How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide .
Step 7: Monitor the response over time
Do not evaluate the medicine solely by the scale. Also consider waist circumference, blood pressure, glucose, physical function, appetite control, adverse effects, nutritional intake, sleep and treatment adherence.
GLP-1 Weight Loss and Muscle: Why the "Quality of Weight Loss" Matters
One of the biggest improvements in GLP-1 discussion during 2025–2026 has been the shift from how much weight is lost toward what the weight loss consists of.
A 2026 systematic review and meta-analysis of randomized controlled trials found that lean mass accounted for roughly 25%–39% of total weight lost with incretin therapies, depending on the drug and analysis. Lifestyle intervention combined with resistance training had a more favorable lean-mass profile in the pooled analysis.
Muscle-preservation checklist
- Prioritize adequate dietary protein.
- Perform progressive resistance training regularly.
- Avoid unnecessarily aggressive calorie restriction.
- Monitor strength and physical function, not only body weight.
- Consider body-composition assessment when clinically useful.
- Pay particular attention to older adults and people with low muscle mass at baseline.
Importantly, a reduction in DXA-measured lean mass does not necessarily mean the same percentage of lost tissue was skeletal muscle. Lean mass also includes water and other non-fat tissues.
Read more: How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)GLP-1 Side Effects: What Is Common and What Requires Attention?
Gastrointestinal adverse effects are among the most frequent problems with semaglutide, tirzepatide and orforglipron. Symptoms may be most noticeable during dose escalation and may lessen over time for some patients.
↔ Swipe the table sideways to see all columns on mobile.
| Issue | Examples | Why it matters |
|---|---|---|
| Common GI effects | Nausea, vomiting, diarrhea, constipation, abdominal discomfort, reflux, dyspepsia | Can impair food and fluid intake; may affect adherence. |
| Dehydration | Persistent vomiting or diarrhea, dizziness, reduced urination | Can contribute to kidney injury, especially in vulnerable patients. |
| Pancreatitis | Persistent or severe abdominal pain, sometimes radiating to the back | Requires urgent medical assessment. |
| Gallbladder disease | Right-upper-abdominal pain, fever, nausea, jaundice | May require clinical evaluation and imaging. |
| Hypoglycemia | Sweating, shaking, confusion, weakness | Risk rises particularly when used with insulin or insulin secretagogues. |
| Serious allergic reaction | Swelling, difficulty breathing, severe rash | Requires prompt medical attention. |
Thyroid C-cell tumor warning
The major GLP-1 labels include a boxed warning related to thyroid C-cell tumors observed in rodents. The clinical relevance to humans has not been established. Wegovy, Zepbound and Foundayo are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with MEN 2 under their U.S. labeling.
Pregnancy
Weight-loss treatment should not be casually continued during pregnancy. Product labels contain pregnancy warnings and specific recommendations. Anyone who is pregnant, planning pregnancy or experiencing a possible pregnancy should discuss the medicine promptly with a clinician.
Surgery and anesthesia
GLP-1 medicines delay gastric emptying, and the labels include warnings concerning pulmonary aspiration during general anesthesia or deep sedation. Patients should tell the anesthesia and surgical teams that they are taking a GLP-1 or incretin medicine.
How Much Does GLP-1 Weight Loss Treatment Cost in 2026?
Cost is highly location-dependent. Insurance coverage, government programs, deductibles, pharmacy pricing, dose and manufacturer savings programs can all change the final amount paid.
The following are U.S. manufacturer self-pay examples available in September 2026. They are not global prices and are subject to eligibility requirements and program changes.
↔ Swipe the table sideways to see all columns on mobile.
| Product | Example U.S. self-pay pricing | Important qualification |
|---|---|---|
| Wegovy pill | Starting at $149/month for 1.5 mg; higher-dose tablet pricing rises by dose | Manufacturer program; eligibility and terms apply. |
| Wegovy injection | Starting at $199/month under the manufacturer's current program; Wegovy HD 7.2 mg listed at $399/month | Current manufacturer self-pay programs and introductory pricing can change. |
| Foundayo | Starting at $149/month; current promotional pricing varies by dose | U.S. LillyDirect/self-pay programs have dose-specific terms. |
| Zepbound | Starting at $299/month for the 2.5 mg dose; $399 for 5 mg; $449 for higher doses under the current self-pay journey offer | Offer conditions include refill timing for certain doses. |
Manufacturer pricing pages should be checked before publication or purchase because savings programs can change without notice.
Do not compare only the monthly sticker price
A meaningful cost comparison should include:
- Insurance coverage
- Actual dose required
- Pharmacy or dispensing fees
- Consultation and monitoring costs
- Laboratory testing when clinically indicated
- Need for long-term treatment
- Cost of managing side effects or complications
- Country-specific regulatory and availability issues
What About Compounded Semaglutide or Tirzepatide?
Compounded GLP-1 medicines require a separate discussion from FDA-approved products. A compounded preparation is not automatically equivalent to the branded FDA-approved medication.
In 2026, the FDA continued to emphasize concerns about unapproved compounded semaglutide and tirzepatide, including issues involving misleading marketing, product quality, dosing and adverse events.
The FDA also specifically warned that some compounded semaglutide products have used salt forms such as semaglutide sodium or semaglutide acetate, which are different active ingredients from the semaglutide used in FDA-approved products.
Because U.S. compounding rules continue to evolve, always verify the current FDA position and the regulatory status of the specific product and pharmacy.
What Happens When You Stop a GLP-1 Medicine?
One of the most important lessons from obesity research is that weight regain after stopping therapy is common. This should be discussed before treatment starts, not after a patient reaches a target weight.
Semaglutide withdrawal data
In the STEP 1 extension, participants who stopped semaglutide after 68 weeks regained a substantial portion of their prior weight loss during the following year. The investigators reported that approximately two-thirds of the weight previously lost was regained.
Tirzepatide withdrawal data
Randomized withdrawal evidence from SURMOUNT-4 also found substantial weight regain after tirzepatide withdrawal in many participants. Greater regain was associated with reversal of several cardiometabolic improvements.
That does not mean every patient must remain on the same drug indefinitely. It means discontinuation, dose reduction, switching, or maintenance treatment should be planned clinically rather than assumed to be consequence-free.
Who May Need Extra Caution?
Special consideration may be appropriate for people with:
- Personal or family history of medullary thyroid carcinoma or MEN 2
- Severe gastrointestinal disease or gastroparesis
- Previous pancreatitis
- Gallbladder disease
- Diabetic retinopathy or rapidly changing glucose control
- Kidney disease or vulnerability to dehydration
- Pregnancy or plans for pregnancy
- Complex diabetes regimens involving insulin or sulfonylureas
- Multiple oral medicines where delayed gastric emptying could matter
- Very low muscle mass, frailty or high risk of sarcopenia
- Upcoming surgery or sedation
These are not automatic reasons that treatment is impossible. They are reasons for individualized clinical review.
GLP-1 Treatment Should Be Bigger Than the Injection or Pill
The most durable approach to obesity treatment combines medication when appropriate with nutrition, physical activity, sleep, behavioral support and monitoring.
The World Health Organization's 2025 guideline describes GLP-1 therapy as part of comprehensive chronic obesity care and conditionally recommends long-term pharmacotherapy for adults with obesity while emphasizing healthy diet, physical activity and professional support.
A practical 2026 framework
What About "Natural GLP-1 Boosters" and Supplements?
Foods, fiber, protein, exercise and other lifestyle factors can influence appetite, glucose regulation and gut hormones, but they should not be presented as equivalent to prescription GLP-1 receptor agonists.
A supplement marketed as a "natural Ozempic" is not automatically pharmacologically equivalent to semaglutide, tirzepatide or orforglipron. Claims of dramatic weight loss should be evaluated against randomized clinical evidence rather than advertising language.
GLP-1 Selection: A Neutral Decision Matrix
Rather than assigning a universal winner, use the following questions with a clinician:
↔ Swipe the table sideways to see all columns on mobile.
| Question | Why it matters |
|---|---|
| Do I prefer a pill or a weekly injection? | Route and dosing frequency can influence adherence. |
| How much weight loss is clinically appropriate? | The goal should reflect health outcomes rather than an arbitrary number. |
| Do I have cardiovascular disease? | Specific cardiovascular outcome indications may influence the discussion. |
| Do I have moderate-to-severe obstructive sleep apnea with obesity? | Zepbound has a specific U.S. FDA indication in this population. |
| How sensitive am I to gastrointestinal effects? | GI tolerability can determine whether treatment can be sustained. |
| What medications do I already take? | Drug interactions and glucose-lowering effects can be clinically important. |
| How will muscle and nutrition be protected? | Large amounts of weight loss can include lean mass. |
| What happens if I stop? | Weight regain is common after withdrawal and should be discussed in advance. |
| What can I realistically afford long term? | Insurance and self-pay costs can become major determinants of adherence. |
| What is actually approved and available where I live? | FDA approvals do not automatically apply to Malaysia or other countries. |
The 2026 GLP-1 Bottom Line
GLP-1 obesity treatment has become more diverse, not simpler. In 2026, the U.S. landscape includes weekly semaglutide, higher-dose Wegovy HD, oral Wegovy, weekly tirzepatide and the newer oral GLP-1 drug Foundayo.
The strongest evidence does not support a single medicine as the universal answer for every patient. Instead, the evidence supports individualized treatment selection based on the patient's goals, medical history, treatment response, tolerability, route preference, comorbidities, access and long-term maintenance plan.
Most importantly, successful obesity treatment should be judged by more than the number on the scale. Preserving muscle, maintaining nutritional adequacy, improving metabolic health and sustaining results over time are all part of the equation.
Frequently Asked Questions
What is the biggest GLP-1 weight-loss update in 2026?
The U.S. treatment landscape expanded significantly. Wegovy now includes an oral formulation and the higher-dose 7.2 mg Wegovy HD injection, while Foundayo (orforglipron) became an FDA-approved once-daily oral GLP-1 receptor agonist.
Is tirzepatide a GLP-1 medicine?
Tirzepatide activates both GLP-1 and GIP receptors, so it is more precisely described as a dual GLP-1/GIP agonist.
Is Wegovy better than Zepbound?
The available evidence should be compared rather than reduced to a universal ranking. SURMOUNT-5 directly found greater average weight reduction with tirzepatide than semaglutide in its specific study population, while semaglutide has an established FDA cardiovascular-risk-reduction indication for a defined population with cardiovascular disease and overweight or obesity. Patient factors and treatment goals matter.
Is there an oral GLP-1 for weight loss in 2026?
Yes. In the United States, oral Wegovy (semaglutide) and Foundayo (orforglipron) are approved oral options for adult weight management.
Can GLP-1 medicines cause muscle loss?
Some lean mass is commonly lost during substantial weight reduction. Current evidence supports adequate protein, resistance training and appropriate monitoring to help preserve muscle and physical function.
Will I regain weight if I stop a GLP-1?
Weight regain is common after withdrawal. Semaglutide and tirzepatide withdrawal studies have shown substantial regain in many participants, supporting long-term obesity-management planning.
Are Ozempic and Wegovy the same medicine?
Both contain semaglutide, but their U.S. brands and FDA-approved indications differ. Wegovy is the semaglutide brand used for chronic weight management and has additional labeled indications. Ozempic is primarily the diabetes brand in the United States.
Are Mounjaro and Zepbound the same medicine?
Both contain tirzepatide, but the U.S. brands have different labeled indications. Mounjaro is the diabetes brand, while Zepbound is the obesity brand and also has a U.S. indication for moderate-to-severe obstructive sleep apnea in adults with obesity.
Are compounded GLP-1 drugs the same as FDA-approved products?
No. A compounded product is not automatically equivalent to an FDA-approved branded medicine. Patients should verify the active ingredient, formulation, source, dosing and applicable regulatory status.
Don’t Just Start GLP-1—Optimize It
Sources & References
This article prioritizes FDA prescribing information, FDA regulatory announcements, randomized clinical trials, PubMed-indexed research and WHO guidance.
-
U.S. FDA — Wegovy / semaglutide labeling
FDA Prescribing Information for Wegovy -
U.S. FDA — Wegovy HD 7.2 mg approval
FDA: Higher-dose semaglutide / Wegovy HD -
U.S. FDA — Foundayo / orforglipron approval
FDA: Foundayo approval -
U.S. FDA — Foundayo prescribing information
FDA Foundayo Label -
U.S. FDA — Zepbound prescribing information
FDA Zepbound Label -
SURMOUNT-5 — Tirzepatide vs. Semaglutide
Aronne LJ, et al. N Engl J Med. 2025;393:26–36.
DOI: 10.1056/NEJMoa2416394 -
STEP UP — Semaglutide 7.2 mg
Wharton S, et al. Lancet Diabetes Endocrinol. 2025;13(11):949–963.
DOI: 10.1016/S2213-8587(25)00226-8 -
OASIS 4 — Oral semaglutide 25 mg
Wharton S, et al. N Engl J Med. 2025;393:1077–1087.
DOI: 10.1056/NEJMoa2500969 -
ATTAIN-1 — Orforglipron
Wharton S, et al. N Engl J Med. 2025;393:1796–1806.
DOI: 10.1056/NEJMoa2511774 -
Semaglutide withdrawal / weight regain
Wilding JPH, et al. Diabetes Obes Metab. 2022;24:1553–1564.
DOI: 10.1111/dom.14725 -
Lean mass and incretin therapy
2026 systematic review and meta-analysis of randomized controlled trials.
PubMed: PMID 41877354 -
WHO — GLP-1 therapies for obesity
World Health Organization, 2025 global guideline and supporting information.
WHO GLP-1 obesity guideline overview -
FDA — Compounded GLP-1 policies and safety
FDA: compounded GLP-1 policy update -
Manufacturer pricing references — U.S.
Wegovy cost and coverage | Foundayo pricing | Zepbound pricing
Editorial note: Drug approvals, indications, pricing programs and prescribing information can change. This page uses U.S. FDA information as its regulatory reference point. Readers outside the United States should verify current authorization, availability, prescribing requirements and pricing with their own national regulator, pharmacist or physician.
Related GLP-1 Guides
Continue exploring the GLP-1 evidence library:
.png)
.png)
.png)
.jpg)
Comments